COVID-19 & Hematologic Malignancies: Expert Insights. A 6-Week Webcast Series.

COVID-19 & Hematologic Malignancies: Expert Insights. A 6-Week Webcast Series.

On-Demand Webcast
Episode 1. Effective Management from New York to California

A roundtable discussion with experts in lymphoma, myeloma, and infectious disease.

Joseph R. Mikhael, MD, MEd, FRCPC, John P. Leonard, MD, Nina Shah, MD, and Michael J. Satlin, MD.

Click Here to Launch Episode 1

Episode 2. Lymphoma Update

A focused discussion with a world-renowned expert on effective management of patients with lymphoma during the COVID-19 pandemic.

Joseph R. Mikhael, MD, MEd, FRCPC and John P. Leonard, MD.

Episode will launch June 1st

Episode 3. Myeloma Update

A focused discussion with a world-renowned expert on effective management of patients with myeloma during the COVID-19 pandemic.

Joseph R. Mikhael, MD, MEd, FRCPC and Nina Shah, MD.

Episode will launch June 3rd


Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email

Intended Learners

This activity is intended for clinicians who encounter patients with hematologic malignancies, including hematologists; hematologic, medical, radiation, and surgical oncologists; and other HCPs, such as pathologists, internists/hospitalists, infectious disease specialists, pulmonologists, critical care specialists, medical students, oncology nurses, NPs, PAs, pharmacists, phlebotomists, and clinical laboratory technologists working as part of the multidisciplinary oncology team during the COVID-19 pandemic.

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  1. Describe the epidemiology, pathology and current treatment strategies of COVID-19  
  2. Develop approaches to limit patient and provider exposure to SARS-CoV-2 while effectively managing hematologic malignancies 
  3. Evaluate current COVID-19 treatment strategies for potential interactions with anticancer agents
  4. Identify, mitigate, and manage current and prospective diagnostic, therapeutic, and monitoring challenges in oncology care due to the reallocation of health resources as a result of the COVID-19 pandemic 
Educational Support

This program was supported through educational grants from Bristol Myers Squibb, Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer Inc. 


This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.


This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.


North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.


NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.